ACADIA Pharmaceuticals reported a GAAP loss of $110.319 million for the six months of 2021, down 15.2% from $130.164 million in the previous year. Revenue increased 10.8% to $221.775 million from $200.171 million a year earlier.
ACADIA Pharmaceuticals reported a GAAP loss of $110.319 million for the six months of 2021, down 15.2% from $130.164 million in the previous year. Revenue increased 10.8% to $221.775 million from $200.171 million a year earlier. 
ir.acadia-pharm.com
English (US) 